Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar ...

| DelveInsight The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based ...

Conference Call Begins at 4:30 p.m. Eastern Time TodayEMERYVILLE, Calif.--(BUSINESS WIRE)--$OABI #OABI--OmniAb, Inc. (NASDAQ: ...

The "Head and Neck Cancer Therapeutics Market – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032" report has ...

Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - ...

The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032 ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

During the fourth quarter of 2025, the Fund returned 13.10% (Institutional Shares), outperforming the Russell 3000 Index ...

Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...

Syndax Pharmaceuticals Inc (SNDX) reports significant revenue increases and strategic progress, positioning itself for continued growth amidst competitive challenges.

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.